In addition, modest changes in several genes associated with enhanced tumor growth and progression, such as collagen VI (Col6a1 and Col6a3), ATPase Phospholipid Transport-11a (Atp11a) and epithelial membrane protein 1 (Emp1), as well as a modest increase in expression of the Myeloid-associated Differentiation marker (Myadm), a reported negative prognostic biomarker in NSCLC (25–29). The gene discussed is COL6A3; the disease is non-small cell lung carcinoma.